Insight into the siRNA transmembrane delivery—From cholesterol conjugating to tagging

Focus Article

Yan Zheng, Wanyi Tai

Published Online: Dec 01 2019

DOI: 10.1002/wnan.1606

Full article on Wiley Online Library: HTML PDF

Can't access this content? Tell your librarian.

Abstract Small interfering RNA (siRNA), combining the features of unprecedented potency, target‐specificity, and the unique sequence‐based disease‐intervention model, has received immense considerations over the past decades in the academia and pharmaceutical industry. siRNA fits the criteria of being drug‐likely enough to meet with the therapeutic purpose, but its clinical translation has been impeded for a long time by the poor efficiency of in vivo delivery. To reach the cytosol where the RNA interference (RNAi) takes place, siRNA delivery faces a serial of systemic and cellular barriers, especially the endosomal sequestration that would prevent the majority of siRNA from cytosol entry. Transmembrane delivery of siRNA represents a new avenue for efficient delivery by bypassing the endosomal pathway. This rationale is bolstered by the high efficiency of viral entry by membrane fusion, but rarely pursued by artificial siRNA delivery systems. Here, this article provides an opinion of transmembrane delivery by hydrophobic modulation of siRNA. We give a brief introduction of the current siRNA delivery modes, including the hydrophobic cholesterol siRNA conjugates. The cholesterol tagging technology is design on the rationale of hydrophobic siRNAs approach, but hydrophobic modulation throughout the whole siRNA backbone for efficient membrane fusion and transmembrane delivery. The challenge and potential of this technology for preclinical development are also discussed. This article is categorized under: Nanotechnology Approaches to Biology > Nanoscale Systems in Biology Therapeutic Approaches and Drug Discovery > Emerging Technologies Biology‐Inspired Nanomaterials > Lipid‐Based Structures Biology‐Inspired Nanomaterials > Nucleic Acid‐Based Structures

The comparison of small interfering RNA (siRNA) delivery modes. (a) siRNA is unable to cross the cell membrane due to the repulsive force from the hydrophobic and anionic lipid bilayer. (b) The cationic siRNA nanoparticle is uptake by cells through the endocytic pathway, but most of the cargoes are degraded during lysosome maturation. (c) Some viruses are able to directly fuse their membrane with cell membrane without being internalized by endocytosis. (d) Chol‐siRNA inserts its cholesterol tail into membrane and triggers the endocytosis. (e) The tagged siRNA is able to fuse with cell membrane because of the hydrophobic modulation throughout the siRNA surface. The tagged siRNA eventually slips into the cytosol and leave the tags on the cell membrane

[ Normal View | Magnified View ]

The cholesterol tagging technology for cytosol delivery of small interfering RNA (siRNA). (a) The tagging technology decorates siRNA with six copies of cholesterol molecules by chelation. It eventually transforms the hydrophilic siRNA into membrane compatible and permeable. (b) The chemical structure of tags. (c) The amphiphilic chol‐siRNA fails to fuse into cell membrane after it inserts its cholesterol tail into lipid bilayer, because the hydrophobic interior of lipid bilayer is repulsive to the hydrophilic and polyanionic siRNA block (upper panel). Membrane fusion of the tagged siRNA is initiated by the insertion of its first cholesterol tail into cell membrane. Other tails outside of membrane provide a driving force to pull siRNA into cells because of the attraction of these cholesterol tails to lipid bilayer (bottom panel). The driving force disappears until the whole siRNA is slipping into the cytosol

[ Normal View | Magnified View ]

Hydrophobic modification of small interfering RNA (siRNA). (a) Structures of chol‐siRNA (upper panel) and sd‐rxRNA (bottom panel). (b) siRNA conjugated with α‐tocopherol (left), palmitic acid (middle) and PC docosahexaenoic acid (right). (c) siRNA prodrug by bioreversible modification on phosphate groups of siRNA backbone. (Reprinted with permission from Meade et al. (). Copyright 2014 Nature Publishing Group) (d) The phosphate groups of siRNA are unmasked by thioesterase in the cytoplasm

[ Normal View | Magnified View ]

References

Abou Matar,, T., & Karam,, P. (2018). The role of hydrophobicity in the cellular uptake of negatively charged macromolecules. Macromolecular Bioscience, 18(2), 1700309.
Adams,, D., Gonzalez‐Duarte,, A., O`Riordan,, W. D., Yang,, C. C., Ueda,, M., Kristen,, A. V., … Suhr,, O. B. (2018). Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. The New England Journal of Medicine, 379(1), 11–21.
Allolio,, C., Magarkar,, A., Jurkiewicz,, P., Baxova,, K., Javanainen,, M., Mason,, P. E., … Jungwirth,, P. (2018). Arginine‐rich cell‐penetrating peptides induce membrane multilamellarity and subsequently enter via formation of a fusion pore. Proceedings of the National Academy of Sciences of the United States of America, 115(47), 11923–11928.
Benizri,, S., Gissot,, A., Martin,, A., Vialet,, B., Grinstaff,, M. W., & Barthelemy,, P. (2019). Bioconjugated oligonucleotides: Recent developments and therapeutic applications. Bioconjugate Chemistry, 30(2), 366–383.
Bochicchio,, D., Panizon,, E., Monticelli,, L., & Rossi,, G. (2017). Interaction of hydrophobic polymers with model lipid bilayers. Scientific Reports, 7(1), 6357.
Chakraborty,, C., Sharma,, A. R., Sharma,, G., Doss,, C. G. P., & Lee,, S. S. (2017). Therapeutic miRNA and siRNA: Moving from bench to clinic as next generation medicine. Molecular Therapy. Nucleic Acids, 8, 132–143.
Chang,, C. I., Yoo,, J. W., Hong,, S. W., Lee,, S. E., Kang,, H. S., Sun,, X., … Lee,, D. K. (2009). Asymmetric shorter‐duplex siRNA structures trigger efficient gene silencing with reduced nonspecific effects. Molecular Therapy, 17(4), 725–732.
Chernikov,, I. V., Gladkikh,, D. V., Meschaninova,, M. I., Ven`yaminova,, A. G., Zenkova,, M. A., Vlassov,, V. V., & Chernolovskaya,, E. L. (2017). Cholesterol‐containing nuclease‐resistant siRNA accumulates in tumors in a carrier‐free mode and silences MDR1 gene. Molecular Therapy. Nucleic Acids, 6, 209–220.
Chernikov,, I. V., Vlassov,, V. V., & Chernolovskaya,, E. L. (2019). Current development of siRNA bioconjugates: From research to the clinic. Frontiers in Pharmacology, 10, 444.
Choi,, C. K. K., Zhang,, L., & Choi,, C. H. J. (2018). Efficient siRNA delivery with non‐cationic carriers. Nature Biomedical Engineering, 2(5), 275–276.
Chu,, C. Y., & Rana,, T. M. (2008). Potent RNAi by short RNA triggers. RNA, 14(9), 1714–1719.
Daniel,, M., Reznickova,, J., Handl,, M., Iglic,, A., & Kralj‐Iglic,, V. (2018). Clustering and separation of hydrophobic nanoparticles in lipid bilayer explained by membrane mechanics. Scientific Reports, 8(1), 10810.
Dowdy,, S. F. (2017). Overcoming cellular barriers for RNA therapeutics. Nature Biotechnology, 35(3), 222–229.
Dujardin,, G., & Dujon,, B. (1979). Mutants in yeast affecting ethidium bromide induced rho‐formation and their effects on transmission and recombination of mitochondrial genes. Molecular %26 General Genetics, 171(2), 205–214.
Fayzulin,, R. Z., Perez,, M., Kozhukhar,, N., Spadafora,, D., Wilson,, G. L., & Alexeyev,, M. F. (2015). A method for mutagenesis of mouse mtDNA and a resource of mouse mtDNA mutations for modeling human pathological conditions. Nucleic Acids Research, 43(9), e62.
Fire,, A., Xu,, S., Montgomery,, M. K., Kostas,, S. A., Driver,, S. E., & Mello,, C. C. (1998). Potent and specific genetic interference by double‐stranded RNA in Caenorhabditis elegans. Nature, 391(6669), 806–811.
Geary,, R. S., Norris,, D., Yu,, R., & Bennett,, C. F. (2015). Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Advanced Drug Delivery Reviews, 87, 46–51.
Gilleron,, J., Paramasivam,, P., Zeigerer,, A., Querbes,, W., Marsico,, G., Andree,, C., … Zerial,, M. (2015). Identification of siRNA delivery enhancers by a chemical library screen. Nucleic Acids Research, 43(16), 7984–8001.
Guo,, Y., Terazzi,, E., Seemann,, R., Fleury,, J. B., & Baulin,, V. A. (2016). Direct proof of spontaneous translocation of lipid‐covered hydrophobic nanoparticles through a phospholipid bilayer. Science Advances, 2(11), e1600261.
Harrison,, S. C. (2015). Viral membrane fusion. Virology, 479–480, 498–507.
Hayakawa,, T., Noda,, M., Yasuda,, K., Yorifuji,, H., Taniguchi,, S., Miwa,, I., … Kadowaki,, T. (1998). Ethidium bromide‐induced inhibition of mitochondrial gene transcription suppresses glucose‐stimulated insulin release in the mouse pancreatic beta‐cell line betaHC9. The Journal of Biological Chemistry, 273(32), 20300–20307.
Huang,, Y., Hong,, J., Zheng,, S., Ding,, Y., Guo,, S., Zhang,, H., … Liang,, Z. (2011). Elimination pathways of systemically delivered siRNA. Molecular Therapy, 19(2), 381–385.
Jeong,, J. H., Mok,, H., Oh,, Y. K., & Park,, T. G. (2009). siRNA conjugate delivery systems. Bioconjugate Chemistry, 20(1), 5–14.
Khvorova,, A., & Watts,, J. K. (2017). The chemical evolution of oligonucleotide therapies of clinical utility. Nature Biotechnology, 35(3), 238–248.
Kristen,, A. V., Ajroud‐Driss,, S., Conceicao,, I., Gorevic,, P., Kyriakides,, T., & Obici,, L. (2019). Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin‐mediated amyloidosis. Neurodegenerative Disease Management, 9(1), 5–23.
Kubo,, T., Takei,, Y., Mihara,, K., Yanagihara,, K., & Seyama,, T. (2012). Amino‐modified and lipid‐conjugated dicer‐substrate siRNA enhances RNAi efficacy. Bioconjugate Chemistry, 23(2), 164–173.
Levy,, A., & Ashiri,, A. (1975). Ethidium bromide—An efficient mutagen in higher plants. Mutation Research, Fundamental and Molecular Mechanisms of Mutagenesis, 28(3), 397–404.
Lipfert,, J., Skinner,, G. M., Keegstra,, J. M., Hensgens,, T., Jager,, T., Dulin,, D., … Dekker,, N. H. (2014). Double‐stranded RNA under force and torque: Similarities to and striking differences from double‐stranded DNA. Proceedings of the National Academy of Sciences of the United States of America, 111(43), 15408–15413.
Lorenz,, C., Hadwiger,, P., John,, M., Vornlocher,, H. P., & Unverzagt,, C. (2004). Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorganic %26 Medicinal Chemistry Letters, 14(19), 4975–4977.
Ly,, L. L., Paz,, N. G., Hunstad,, J., & Cauwenbergh,, G. (2015). Update on phase 2 clinical trial results of RXI‐109 treatment to reduce the formation of hypertrophic dermal scars. Journal of the American Academy of Dermatology, 72(5), AB273.
Ly,, S., Navaroli,, D. M., Didiot,, M. C., Cardia,, J., Pandarinathan,, L., Alterman,, J. F., … Khvorova,, A. (2017). Visualization of self‐delivering hydrophobically modified siRNA cellular internalization. Nucleic Acids Research, 45(1), 15–25.
Madani,, F., Lindberg,, S., Langel,, U., Futaki,, S., & Graslund,, A. (2011). Mechanisms of cellular uptake of cell‐penetrating peptides. Journal of Biophysics, 2011, 414729.
Meade,, B. R., Gogoi,, K., Hamil,, A. S., Palm‐Apergi,, C., van den Berg,, A., Hagopian,, J. C., … Dowdy,, S. F. (2014). Efficient delivery of RNAi prodrugs containing reversible charge‐neutralizing phosphotriester backbone modifications. Nature Biotechnology, 32(12), 1256–1261.
Nakamura,, H., & Watano,, S. (2018). Direct permeation of nanoparticles across cell membrane: A review. Kona Powder and Particle Journal, 35, 49–65.
Nishina,, K., Unno,, T., Uno,, Y., Kubodera,, T., Kanouchi,, T., Mizusawa,, H., & Yokota,, T. (2008). Efficient in vivo delivery of siRNA to the liver by conjugation of alpha‐tocopherol. Molecular Therapy, 16(4), 734–740.
Petrova,, N. S., Chernikov,, I. V., Meschaninova,, M. I., Dovydenko,, I. S., Venyaminova,, A. G., Zenkova,, M. A., … Chernolovskaya,, E. L. (2012). Carrier‐free cellular uptake and the gene‐silencing activity of the lipophilic siRNAs is strongly affected by the length of the linker between siRNA and lipophilic group. Nucleic Acids Research, 40(5), 2330–2344.
Poranen,, M. M., Daugelavicius,, R., Ojala,, P. M., Hess,, M. W., & Bamford,, D. H. (1999). A novel virus‐host cell membrane interaction. Membrane voltage‐dependent endocytic‐like entry of bacteriophage straight phi6 nucleocapsid. The Journal of Cell Biology, 147(3), 671–682.
Roy Chowdhury,, A., Bakshi,, R., Wang,, J., Yildirir,, G., Liu,, B., Pappas‐Brown,, V., … Englund,, P. T. (2010). The killing of African trypanosomes by ethidium bromide. PLoS Pathogens, 6(12), e1001226.
Sahay,, G., Querbes,, W., Alabi,, C., Eltoukhy,, A., Sarkar,, S., Zurenko,, C., … Anderson,, D. G. (2013). Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nature Biotechnology, 31(7), 653–658.
Soutschek,, J., Akinc,, A., Bramlage,, B., Charisse,, K., Constien,, R., Donoghue,, M., … Vornlocher,, H. P. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature, 432(7014), 173–178.
Sun,, X., Rogoff,, H. A., & Li,, C. J. (2008). Asymmetric RNA duplexes mediate RNA interference in mammalian cells. Nature Biotechnology, 26(12), 1379–1382.
Tai,, W. (2019a). Chemical modulation of siRNA lipophilicity for efficient delivery. Journal of Controlled Release, 307, 98–107.
Tai,, W. (2019b). Current aspects of siRNA bioconjugate for in vitro and in vivo delivery. Molecules, 24(12), 2211.
Tai,, W., & Gao,, X. (2017). Functional peptides for siRNA delivery. Advanced Drug Delivery Reviews, 110–111, 157–168.
Tai,, W., & Gao,, X. (2018). Noncovalent tagging of siRNA with steroids for transmembrane delivery. Biomaterials, 178, 720–727.
Tatiparti,, K., Sau,, S., Kashaw,, S. K., & Iyer,, A. K. (2017). siRNA delivery strategies: A comprehensive review of recent developments. Nanomaterials (Basel), 7(4), 77.
Vaishnaw,, A. K., Gollob,, J., Gamba‐Vitalo,, C., Hutabarat,, R., Sah,, D., Meyers,, R., … Maraganore,, J. (2010). A status report on RNAi therapeutics. Silence, 1(1), 14.
Wang,, S., Guo,, H., Li,, Y., & Li,, X. (2019). Penetration of nanoparticles across a lipid bilayer: Effects of particle stiffness and surface hydrophobicity. Nanoscale, 11(9), 4025–4034.
Warren,, E. B., Aicher,, A. E., Fessel,, J. P., & Konradi,, C. (2017). Mitochondrial DNA depletion by ethidium bromide decreases neuronal mitochondrial creatine kinase: Implications for striatal energy metabolism. PLoS One, 12(12), e0190456.
Werner,, M., & Sommer,, J. U. (2015). Translocation and induced permeability of random amphiphilic copolymers interacting with lipid bilayer membranes. Biomacromolecules, 16(1), 125–135.
Werner,, M., Sommer,, J.‐U., & Baulin,, V. A. (2012). Homo‐polymers with balanced hydrophobicity translocate through lipid bilayers and enhance local solvent permeability. Soft Matter, 8(46), 11714–11722.
Wilson,, R. C., & Doudna,, J. A. (2013). Molecular mechanisms of RNA interference. Annual Review of Biophysics, 42, 217–239.
Wolfrum,, C., Shi,, S., Jayaprakash,, K. N., Jayaraman,, M., Wang,, G., Pandey,, R. K., … Stoffel,, M. (2007). Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nature Biotechnology, 25(10), 1149–1157.
Wooddell,, C. I., Rozema,, D. B., Hossbach,, M., John,, M., Hamilton,, H. L., Chu,, Q., … Lewis,, D. L. (2013). Hepatocyte‐targeted RNAi therapeutics for the treatment of chronic hepatitis B virus infection. Molecular Therapy, 21(5), 973–985.
Yong,, C. W. (2015). Study of interactions between polymer nanoparticles and cell membranes at atomistic levels. Philosophical Transactions of the Royal Society of London, Series B, 370(1661), 20140036.
Yu,, M., Shi,, Y., Wei,, X., Yang,, Y., Zhou,, Y., Hao,, X., … Niu,, R. (2007). Depletion of mitochondrial DNA by ethidium bromide treatment inhibits the proliferation and tumorigenesis of T47D human breast cancer cells. Toxicology Letters, 170(1), 83–93.

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

Insight into the siRNA transmembrane delivery—From cholesterol conjugating to tagging

Browse by Topic

Access to this WIREs title is by subscription only.

The latest WIREs articles in your inbox